Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THN391 in Early Alzheimer's Disease
NCT06814730Phase 1Active, not recruiting
- Sponsor
- Therini Bio
- Start
- Jul 2025
- Primary completion
- Mar 2027
- Modality
- IgG Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of THN391 in Alzheimer's disease (AD) (4 cohorts), sponsored by Therini Bio. Primary endpoints: Adverse Events, Serious Adverse Events and 4 more. Started Jul 2025; status: active, not recruiting.
02
Drugs
THN391
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06814730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06814730.